Stocks of Allarity Therapeutics Inc (NASDAQ:ALLR) traded higher last session on Wall Street, down -13.99% to $0.50.
ALLR stock price is now -17.45% away from the 50-day moving average and -98.59% away from the 200-day moving average. The market capitalization of the company currently stands at $2.09M.
A total of 1.29% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $0.5134 for Allarity Therapeutics Inc (NASDAQ: ALLR). During the past 12 months, Allarity Therapeutics Inc has had a low of $0.45 and a high of $1890.00. The fifty day moving average price for ALLR is $0.6039 and a two-hundred day moving average price translates $35.4196 for the stock.
The latest earnings results from Allarity Therapeutics Inc (NASDAQ: ALLR) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$2.24, beating analysts’ expectations of -$8.17 by 5.93. This compares to -$702.78 EPS in the same period last year. The company reported revenue of $4.43 million for the quarter, compared to $4.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.98 percent.
Allarity Therapeutics Inc(ALLR) Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
